Evidence map›Paper›PMID 25715874›Full record

ArticleScientific reports2015

SNORD76, a box C/D snoRNA, acts as a tumor suppressor in glioblastoma.

Luyue Chen, Lei Han, Jianwei Wei, Kailiang Zhang, Zhendong Shi, Ran Duan, Shouwei Li, Xuan Zhou, Peiyu Pu, Jianning Zhang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 64 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Selective remodeling of snoRNA and sdRNA biology in glioblastoma.Frontiers in cell and developmental biology · 2026
    Review
  5. Review
  6. Translational cancer research · 2025
    Article
  7. The zebrafish (NAR genomics and bioinformatics · 2025
    Article
  8. GL4SDA: Predicting snoRNA-disease associations using GNNs and LLM embeddings.Computational and structural biotechnology journal · 2025
    Article
  9. Article
  10. Article
  11. Review
  12. SnoRNAs: Exploring Their Implication in Human Diseases.International journal of molecular sciences · 2024
    Review
  13. The multifaceted functions of long non-coding RNAExpert reviews in molecular medicine · 2024
    Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Luyue Chen1] Laboratory of Neuro-Oncology, Department of Neurosurgery, Tianjin Neurological Institute, Tianjin Medical University General Hospital [2] Key Laboratory of Neurotrauma, Variation, and Regeneration, Ministry of Education and Tianjin Municipal Government [3] Chinese Glioma Cooperative Group (CGCG), China.
Lei Han1] Laboratory of Neuro-Oncology, Department of Neurosurgery, Tianjin Neurological Institute, Tianjin Medical University General Hospital [2] Key Laboratory of Neurotrauma, Variation, and Regeneration, Ministry of Education and Tianjin Municipal Government [3] Chinese Glioma Cooperative Group (CGCG), China.
Jianwei Wei1] Laboratory of Neuro-Oncology, Department of Neurosurgery, Tianjin Neurological Institute, Tianjin Medical University General Hospital [2] Key Laboratory of Neurotrauma, Variation, and Regeneration, Ministry of Education and Tianjin Municipal Government [3] Chinese Glioma Cooperative Group (CGCG), China.
Kailiang Zhang1] Laboratory of Neuro-Oncology, Department of Neurosurgery, Tianjin Neurological Institute, Tianjin Medical University General Hospital [2] Key Laboratory of Neurotrauma, Variation, and Regeneration, Ministry of Education and Tianjin Municipal Government [3] Chinese Glioma Cooperative Group (CGCG), China.
Zhendong Shi1] Laboratory of Neuro-Oncology, Department of Neurosurgery, Tianjin Neurological Institute, Tianjin Medical University General Hospital [2] Key Laboratory of Neurotrauma, Variation, and Regeneration, Ministry of Education and Tianjin Municipal Government [3] Chinese Glioma Cooperative Group (CGCG), China.
Ran Duan1] Chinese Glioma Cooperative Group (CGCG), China [2] Beijing Tian Tan Hospital, Capital Medical University.
Shouwei Li1] Chinese Glioma Cooperative Group (CGCG), China [2] Beijing Sanbo Brain Hospital, Capital Medical University.
Xuan Zhou1] Laboratory of Neuro-Oncology, Department of Neurosurgery, Tianjin Neurological Institute, Tianjin Medical University General Hospital [2] Key Laboratory of Neurotrauma, Variation, and Regeneration, Ministry of Education and Tianjin Municipal Government [3] Chinese Glioma Cooperative Group (CGCG), China.
Peiyu Pu1] Laboratory of Neuro-Oncology, Department of Neurosurgery, Tianjin Neurological Institute, Tianjin Medical University General Hospital [2] Key Laboratory of Neurotrauma, Variation, and Regeneration, Ministry of Education and Tianjin Municipal Government [3] Chinese Glioma Cooperative Group (CGCG), China.
Jianning Zhang1] Laboratory of Neuro-Oncology, Department of Neurosurgery, Tianjin Neurological Institute, Tianjin Medical University General Hospital [2] Key Laboratory of Neurotrauma, Variation, and Regeneration, Ministry of Education and Tianjin Municipal Government [3] Chinese Glioma Cooperative Group (CGCG), China.
Chunsheng Kang1] Laboratory of Neuro-Oncology, Department of Neurosurgery, Tianjin Neurological Institute, Tianjin Medical University General Hospital [2] Key Laboratory of Neurotrauma, Variation, and Regeneration, Ministry of Education and Tianjin Municipal Government [3] Chinese Glioma Cooperative Group (CGCG), China.
Tianjin Medical University General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is associated with disproportionately high morbidity and mortality, reflecting the need to develop new diagnostic and therapeutic targets for this disease. Recently, accumulating evidence has suggested that small nucleolar RNAs (snoRNAs) are gaining prominence and are more actively involved in tumorigenesis than previously thought. However, no report concerning the implication of snoRNAs in glioma has been published to date. In our study, SNORD76 was first found to be inversely associated with Hox Transcript Antisense Intergenic RNA (HOTAIR) knockdown, and surprisingly, forcibly expressed SNORD76 inhibited proliferation and growth of glioma cells. Moreover, downregulation of SNORD76 led to a more malignant phenotype. The pleiotropy of SNORD76 overexpression could be achieved at least partially through inducing cell cycle arrest at S phase by affecting the Rb-associated cell cycle regulation. Enforced SNORD76 expression in orthotopic tumors resulted in decreased tumor growth and the reduction of tumor volume. Additionally, in surgically resected glioma tissues, SNORD76, not its host gene, was associated with the WHO classification and was selectively downregulated in GBM (WHO grade IV). Collectively, our study adds to a growing body of evidence for the participation of snoRNAs in gliomagenesis and is the first to implicate a snoRNA in glioblastoma.

Indexed as

AnimalsCell Line, TumorCell ProliferationGenes, Tumor SuppressorGlioblastomaHumansMice, NudeNeoplasm TransplantationRNA, Long NoncodingS Phase Cell Cycle CheckpointsTumor BurdenGAS5 long non-coding RNA, humanRNA, Long Noncoding

Identifiers

PMID25715874
PMCPMC5390076
OpenAlexW2063155123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.